Business solution
KLIFO CMC Development Solutions applies scientific excellence to ensure optimal development of your drug candidate. Our experts ensure that your drug presentation is suitable for the relevant pre-clinical and clinical stages. This ensures that information related to your product inspires confidence at the relevant regulatory agencies so that your drug can readily progress to the next stages of development.
Hanne Wulff Nielsen
VP
Hanne holds a Ph.D. in biopharmaceutics and has more than 25 years of pharma industry experience within pharmaceutical product development, business development, project and vendor management, marketing and medical affairs. She joined KLIFO in January 2019 and prior to this she has held specialist and leadership positions in large pharmaceutical companies and in biotech.
Direct/mobile: + 45 44 222 903
Email: moc.ofilk@neslein.ennah
Expertise &
therapy areas
Expertise
At KLIFO CMC Development Solutions, we offer expert CMC consulting throughout all R&D stages including:
- CMC project management
- Expert support in formulation and analytical development
- Development of quality target product profiles (qTPP) and identification of critical quality attributes (CQA’s)
- Implementation of Quality by Design (QbD) in drug development
- Performing and facilitating root-cause investigations
- Upscaling of manufacturing processes and transfer to CMO, including management of CMOs
- Preparation of reports and documentation to support regulatory filings
- Planning and conducting of CMC due diligence (DD), including reporting and recommendation
- Medical devices:
- Drug-device combinations
- Container closure selection
Our expert staff
-
Jørn DrustrupSenior CMC Expert
Jørn holds a Master of Pharmacy. Furthermore, a PhD degree within the area of Drug Delivery via Prodrugs. Jørn joined KLIFO in August 2019. He has more than 33 years of experience with special focus on early stage R&D/CMC-related topics, including formulation, alternative drug delivery concepts and the interrelationship between formulation and administration devices.
Senior advisors
- Anders Vagnø Pedersen (DK)
- Babak Jamali (DK)
- Jens Bukrinski (DK)
- Jørgen Lang Pedersen (DK)
- Julia E. Diederichs (DE)
- Kaare Gyberg Rasmussen (DK)
- Kaare Lund (DK)
- Karen Rørbæk (DK)
- Karin Liltorp (DK)
- Lars Foldager (DK)
- Lars Gyldenvang (DK)
- Marianne Svärd (SE)
- Mats Reslow (SE)
- Timo Schmidt (CH)